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Abstract. – OBJECTIVE: The clinic use of al-
pha Lipoic Acid (ALA) is linked to its capability
to exert antioxidant effects and, more interest-
ingly, to counteract the pathologic changes of
complex networks of cytokines, chemokines and
growth factors, restoring their physiological
state. The aim of this randomized controlled clin-
ical trial was to test the contribution of oral sup-
plementation of ALA to the standard treatment
with Progesterone vaginal suppositories, in heal-
ing subchorionic hematomas in patients with
threatened miscarriage. Controls were adminis-
tered only Progesterone suppositories.
PATIENTS AND METHODS: Nineteen pregnant
women in the first trimester of gestation, with
threatened miscarriage and ultrasound evidence
of subchorionic hematoma, were included in the
trial and randomly divided in two groups: con-
trols, treated with 400 mg Progesterone (200 mg
2 times per day), given by vaginal suppositories,
and case study treated with the same Proges-
terone dosage, plus ALA, given orally at the
dose of 600 mg (300 mg 2 times per day, DAV®,
Lo.Li. Pharma srl, Italy). Sixteen patients com-
pleted the trial. Treatment was performed until
complete resolution of the clinical picture.
RESULTS: In both groups, the subjects im-
proved significantly but, in general, a better and
faster evolution in the major signs of threatened
miscarriage was observed in the subjects treat-
ed with ALA and Progesterone. In these patients,
the speed of resorption of subchorionic
hematoma was significantly (p ≤ 0.05) superior
compared to controls. The ALA and Proges-
terone group showed a faster decrease or disap-
pearance of all symptoms than that observed in
the control group, however the difference was
not significant. 
CONCLUSIONS: These preliminary results
suggest that ALA supplementation significantly
contributes to speed up the process of restora-
tion of physiological conditions in threatened
miscarriage and ameliorates the medical condi-
tions of both the mothers and the foetus, proba-
bly modulating the networks of cytokines,
growth factors and other molecules.
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Introduction
Threatened miscarriage is characterized by
vaginal bleeding, other than spotting, and pelvic
pain within the first 20 weeks of gestation. It af-
fects around 20% of women, and spontaneous
abortion occurs approximately in half of these
pregnancies1. Up to 80% of these losses appear
to be caused by genetic abnormalities2. Also in-
flammatory processes and immunologic disor-
ders can induce miscarriage3-4. The presence of a
first-trimester subchorionic hematoma is a suit-
able marker of patients at greater risk for adverse
pregnancy outcome5. In particular, the presence
of a very large first-trimester subchorionic
hematoma has been suggested to be associated
with a 46% risk of adverse pregnancy outcome
(spontaneous abortion and premature rupture of
membranes)6. Therefore, its resorption represents
a fundamental target to prevent preterm delivery.
Th1, Th2, Th17 and regulatory T (Treg) cells7
are essential in immunity8 and pregnancy9 and
are involved in boosting and/or dampening in-
flammation10-12. Th1 cells secrete inflammatory
cytokines, such as Tumor Necrosis Factor (TNF)
and Interferon-gamma (IFN-gamma), but also In-
terleukine-10 (IL-10). Instead, Th2 cells produce
several Interleukins, such as IL-4, IL-10, etc.8 Fi-
nally, Th17 cells, similarly involved in
pregnancy13, produce the proinflammatory cy-
tokine IL-177,14-15. On the other side, Treg cells
play an essential role in the development of im-
munoregulation and induction of tolerance. IL-1
beta, a pro-inflammatory cytokine, mainly re-
leased by monocytes and macrophages, is also
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involved in gestation, exerting either an aborto-
genic effect (probably prevailing) or a protection
from miscarriage16. The maintenance of a healthy
gestation needs an adequate interplay between
Th1- and Th2-mediated immunity. Furthermore,
a broad spectrum of different molecules, such as
growth factors, cytokines and chemokines, are
implicated in acute wound and in its healing.
TNF-alpha, IL-1 and IL-6 induce inflammation
in the acute wound (as well known, inflammation
is required for fighting infection), and are in-
volved also in reepithelialization17. Vascular En-
dothelial Growth Factor (VEGF) stimulates ep-
ithelialization and collagen deposition in
wounds18, and Alpha-Smooth Muscle Actin (al-
pha-SMA) takes part in fibrogenesis19, i.e. vascu-
logenesis and angiogenesis. Inflammation, extra-
cellular matrix (ECM) degradation and remodel-
ing of new ECM are positively affected also by
matrix metalloproteases (MMPs), though a selec-
tive control of their activity is necessary to avoid
the wound worsening20. 
The use of progesterone in the managing of
threatened miscarriage, is prescribed by thera-
peutic protocols, although, few evidences support
its efficacy21. 
Our aim was to verify whether alpha lipoic
acid (ALA), a natural and safe molecule with an
anti-inflammatory and antioxidant profile22-24,
can improve efficaciously the therapy with prog-
esterone. The reason why ALA was used de-
pends on its capability to counteract the patho-
logic changes of complex networks of cytokines,
chemokines and growth factors, restoring their
physiological state, and in consideration that
such factors are involved also in inducing threat-
ened miscarriage.
The clinical trial has evaluated the innovative
therapeutic effects of ALA, by oral route, and
Progesterone vaginal suppositories, compared
with Progesterone alone, in reducing significant-
ly the subchorionic hematomas and other symp-
toms linked to spontaneous abortion. 
Patients and Methods
Pregnant women with threatened miscarriage
were assessed for eligibility from March 2013 to
February 2014 at the Division of Obstetrics and
Gynecology, University of Perugia, Italy. We ap-
plied the following inclusion criteria: the subjects
had to be between 20 and 40 years old, between
6th and 13th week of physiological pregnancy,
with pelvic pain and/or vaginal bleeding, and
subchorionic hematomas, observed by ultrasound
examination. The exclusion criteria were the
presence of multiple pregnancy, pre-pregnancy or
gestation pathologies (arterial hypertension, ma-
ternal autoimmune diseases, antiphospholipid
syndrome), treatment with anti-hypertensive and
anti-coagulant drugs, that could be confusing fac-
tors. The study was approved by the Bioethics
Committee SIFIOG (Italian Society of Phytother-
apy and Dietary Supplements in Obstetrics and
Gynecology). All pregnant women were in-
formed about the nature of the study and verbally
acceded to participate to it. The clinical trial was
a randomized controlled study, with 1:1 alloca-
tion ratio. The study had two groups: controls,
with 400 mg Progesterone (200 mg 2 times per
day), given by vaginal suppositories, and treated
(case study) with the same Progesterone dosage,
plus ALA (DAV®, Lo.Li. Pharma srl, Rome,
Italy), given orally at the dose of 600 mg (300
mg 2 times per day, in the morning and in the
evening,). In our study we used only these two
groups of treatment, because it was impossible to
add a third arm without treatment, owing to the
Bioethics Committee refusal to accept this possi-
bility. The protocol prescribed to administer all
compounds until complete resolution of the clini-
cal picture. 
Primary outcome: reduction/disappearance of
subchorionic hematoma detected by sonography,
vaginal bleedings, pelvic pain and uterine con-
tractions. The size of the hematoma was com-
pared with the size of the gestational sac during
the examination and classified as small (< 20%
of the gestational sac), medium (20%-50% of the
gestational sac), or large (> 50% of the gestation-
al sac)6. In the case study the hematoma was
medium-sized in five patients, and large in four
cases, whereas three controls had a large
hematoma and four a medium-sized one. Pro-
gressive hematoma resorption during treatment
was calculated as percentage between two subse-
quent time points for each patient and the medi-
um value for each group has been obtained and
compared. With the aim of recording systemati-
cally the changes in pain symptomatology for the
subsequent analysis and evaluation, patients re-
ceived a sheet where they had to note the daily
number of contractions during the time period
between two medical examinations. 
Secondary outcomes: placental abruption, de-
crease of miscarriage incidence and preterm de-
livery. 
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The improvements have been monitored dur-
ing all study, and evaluated respect to the base-
line (t = 0).
Statistical Analysis
Data analysis was performed using GraphPad
Prism software (GraphPad Software, Inc., La Jol-
la, CA, USA). The M-estimator of regression
curve, used for the statistical analysis of signifi-
cance, was calculated, for each patient, consider-
ing only the first 100% value in the healing. The
Mann-Whitney U-test was applied for determin-
ing the significant difference between the two
groups. The level of statistical significance was
set below p = 0.05. 
Results 
Among twenty-nine assessed subjects, with
threatened miscarriage, a total number of nine-
teen pregnant women were included in the study.
The age range was from 26 to 39 years, with a
mean value of 32.5 ± 3.9 years, and a mean body
weight of 58.94 ± 7.01 kg. The mean age in con-
trol group was 31.7 ± 2.56 years, and in treated
group was 33.1 ± 4.75 years. The mean body
weight was, respectively, of 58.7 ± 7.2 kg and
59.11 ± 7.3 kg. The average of gestational age
was 8.7 ± 1.4 weeks in the case study and 8.5 ±
0.4 weeks in the control group. There was no sta-
tistically significant difference between the case
study and the control group in terms of mothers’
ages and gestational ages. There were three drop-
outs: two patients, in the Progesterone group,
failed to complete the study owing to the in-
creased vaginal bleeding and admission to hospi-
tal at the beginning of the trial, whereas one pa-
tient in the case study underwent termination of
pregnancy because of fetal trisomy 21. Among
the sixteen patients, who completed the study,
there were eight nulliparous women in the case
study, and one multigravida (three subjects had a
previous miscarriage), while in the control group,
there were six nulliparous, and one multigravida
(two subjects had previously a miscarriage). No-
body had had caesarean section. Patients were
controlled after a week from the baseline, and
later every fifteen days until the resolution of the
clinical picture. In no case, symptoms not no-
ticed during the 1st medical examination, later af-
flicted the patient. Treatments did not cause any
adverse effect on mother or foetus. 
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Figure 1. A, Subchorionic hematoma (9th week of preg-
nancy) in ALA plus Progesterone group. B, Subchorionic
hematoma reduction (10th week of pregnancy) in ALA plus
Progesterone group. C, Complete subchorionic hematoma
resorption (12th week of pregnancy) in ALA plus Proges-
terone group.
B
A
C
At ultrasounds hematoma appears such as an
anechoic area (i.e., echo free on a sonographic
image) of variable size, located between the uter-
ine wall and the chorionic membrane (Figures
1A, B and C).
The improvement was general, but with a very
different time trend in the healing, which was
clearly much faster in patients treated with ALA
plus Prog (Figure 2A).
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Figure 2. A, Progress of subchorionic hematoma resorption (∆ percentage of Mean ± SEM), detected by sonography at dif-
ferent time points of treatment, in ALA plus Prog. group (n = 9) and Prog. group (n = 7). The size of the hematoma was com-
pared (%) with the size of the gestational sac during the examination. Progressive hematoma resorption during treatment was
calculated as ∆ percentage between two subsequent time points for each patient and the medium value for each group has been
obtained and compared. B, Subchorionic hematoma resorption: statistical significance of the regression slopes (ALA plus
Prog. group vs. Prog. group). Mean ± SEM of M-estimator for ALA plus Prog. Group (n = 9) and Prog. Group (n = 7). The M-
estimator of regression curve, used for the statistical analysis of significance of hematoma resorption, was calculated, for each
patient, considering only the first 100% value in the healing. The two groups were found significantly different (Mann-Whit-
ney U-Test: The U-value is 8. The critical value of U at p ≤ 0.05 is 12. Therefore the result is significant at p ≤ 0.05*).
A B
The two groups were found significantly differ-
ent (Mann-Whitney U-Test: The U-value is 8. The
critical value of U at p ≤ 0.05 is 12. Therefore, the
result is significant at p ≤ 0.05) (Figure 2B).
Concerning the symptoms such as pelvic pain,
uterine contractions, vaginal bleeding and soft
uterus, the changes of these parameters, from the
baseline (t0) to the following medical controls (t1
t3), are shown in Table I.
Only in soft uterus the changes have been the
same in both groups, whereas evident differ-
ences, but not statistically significant, can be ob-
served in parameters such as pelvic pain, uterine
contractions and vaginal bleeding. In both
groups, episodes of threatened miscarriage,
preterm deliveries, placental abruption, were not
recorded.
Discussion
Our preliminary results indicate that patients
treated with ALA plus Progesterone have had a
better and faster evolution of the clinical signs
and symptoms related to threatened miscarriage.
The monitoring of subchorionic hematoma,
vaginal bleeding, pelvic pain, and uterine con-
tractions showed that all signs and symptoms de-
creased or disappeared in the group treated with
ALA plus Progesterone, before than in controls
(Progesterone alone). Indeed, despite the treat-
ments show comparable results in the objective
resolution of uterine contractions (soft uterus),
the results related to the subjective symptoms
(i.e. uterine contractions) highlighted that pa-
tients in the case study showed a faster resolution
of the symptoms, directly improving the life
quality of pregnant women.
In particular, the results obtained for the
hematoma resorption, detected by scan, are of
particular interest. In fact, the ALA plus Proges-
terone group showed a clear improvement, statis-
tically significant, whereas the other effects (on
vaginal bleeding, pelvic pain and uterine contrac-
tions) were not statistically significant.
The use of progesterone in the management of
threatened miscarriage is prescribed by therapeu-
tic protocols, but the real extent of its efficacy in
reducing miscarriages is debated21,25-29. Much
more interesting and innovative is the therapeutic
activity of ALA, a safe natural molecule. The bi-
ological systems synthetize this compound, but it
can be also assimilated in food or nutritional sup-
plements. ALA exerts a powerful anti-inflamma-
tory and antioxidant activity22-24. It is important
to highlight that ALA substantially decreases the
secretion of inflammatory cytokines, such as
TNF-alpha, IL-1beta and IL-17, whereas it stim-
ulates the release of the anti-inflammatory cy-
tokine IL-10; it significantly suppresses the num-
ber and percentage of encephalitogenic Th1 and
Th17 cells, increases splenic Treg-cells, inhibits
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Baseline 1st medical 2nd medical 3rd medical
med. exam. t0 control t1 control t2 control t3
Symptoms ALA+Pr Pr. ALA+Pr. Pr. ALA+Pr. Pr. ALA+Pr. Pr.
(n = 9) (n = 7) (n = 9) (n = 7) (n = 9) (n = 7) (n = 9) (n = 7)
Vag. bleed. 5 (55%) 4 (57%) 1 (11%) 2 (29%) 0 0 0 0
Abd. pain 9 (100%) 7 (100%) 2 (22%) 4 (57%) 0 1 (14%) 0 0
Soft uterus 3 (33%) 4 (57%) 9 (100%) 7 (100%) 9 (100%) 7 (100%) 9 (100%) 7 (100%)
Uter. contr. 8 (89%) 7 (100%) 4 (44%) 7 (100%) 0 5 (71%) 0 1 (14%)*
Table I. Effects of the treatments (ALA + Progesterone or Progesterone) on symptoms of threatened miscarriage.
Data are given as sample size (number and percentage) of each group at different time points: t0: baseline medical examination;
t1: 1 week after baseline medical examination; t2: 3 weeks after baseline medical examination; t3: 5 weeks after baseline med-
ical examination. *The symptom disappeared at the subsequent medical examination.
Conclusions
Our preliminary results suggest that ALA sup-
plementation may play a pivotal role in signifi-
cantly ameliorating the medical conditions of
both the mothers and the foetus, reducing the
complications linked to threatened miscarriage,
and improving the pregnancy outcome.
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